1-2 of 2
Yen-Chao Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy

Free
Mario Giuliano, Huizhong Hu, Yen-Chao Wang, Xiaoyong Fu, Agostina Nardone, Sabrina Herrera, Sufeng Mao, Alejandro Contreras, Carolina Gutierrez, Tao Wang, Susan G. Hilsenbeck, Carmine De Angelis, Nicholas J. Wang, Laura M. Heiser, Joe W. Gray, Sara Lopez-Tarruella, Anne C. Pavlick, Meghana V. Trivedi, Gary C. Chamness, Jenny C. Chang, C. Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 3995–4003.
https://doi.org/10.1158/1078-0432.CCR-14-2728
Published: 31 August 2015
View articletitled, Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Open the PDF for Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy in another window
Includes: Supplementary data
Journal Articles

Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts

Free
Mothaffar F. Rimawi, Lisa S. Wiechmann, Yen-Chao Wang, Catherine Huang, Ilenia Migliaccio, Meng-Fen Wu, Carolina Gutierrez, Susan G. Hilsenbeck, Grazia Arpino, Suleiman Massarweh, Robin Ward, Robert Soliz, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1351–1361.
https://doi.org/10.1158/1078-0432.CCR-10-1905
Published: 15 March 2011
View articletitled, Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts
Open the PDF for Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts in another window